"New Drug Gains Approval for ATTR-CM Following Successful Safety Trials"

The FDA has approved Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM), a serious heart condition. This treatment reduces TTR protein levels, potentially improving outcomes by 28%. CEO Yvonne Greenstreet emphasizes its promise for patient care, while addressing disparities in diagnosis and access among the Black community remains crucial.